Literature DB >> 11196272

Treatment of Langerhans cell histiocytosis with pamidronate.

R P Farran1, E Zaretski, R M Egeler.   

Abstract

A 14-year-old boy with longstanding multisystem Langerhans cell histiocytosis (LCH) had multifocal bone pain unresponsive to chemotherapy, corticosteroids, anti-inflammatories, and narcotic analgesics. He responded to two cycles of intravenous pamidronate, each 90 mg per day on three consecutive days. Two subsequent episodes of deterioration also responded to treatment. The pathophysiology of his bone pain and the likely mechanisms of biphosphonate action are discussed, with emphasis on the molecular and cellular basis of LCH.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11196272     DOI: 10.1097/00043426-200101000-00013

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  16 in total

1.  Distinctive growth pattern in a patient with a delayed diagnosis of Langerhans' cell histiocytosis.

Authors:  Athanasios D Anastasilakis; Gregory A Kaltsas; Georgios Delimpasis; Ludwig Wilkens; George Kanakis; Polyzois Makras
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

2.  Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series.

Authors:  Shanthi Sivendran; Harold Harvey; Allan Lipton; Joseph Drabick
Journal:  Int J Hematol       Date:  2011-04-26       Impact factor: 2.490

3.  Treatment of skeletal Erdheim-Chester disease with zoledronic acid: case report and proposed mechanisms of action.

Authors:  Thitinan Srikulmontree; H Davis Massey; W Neal Roberts
Journal:  Rheumatol Int       Date:  2006-08-25       Impact factor: 2.631

Review 4.  Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.

Authors:  Milen Minkov
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

5.  [Clinical features and prognosis of Langerhans cell histiocytosis in children: an analysis of 34 cases].

Authors:  Dan Li; Hui Li; Hong Shi
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-06

6.  Addition of pamidronate to chemotherapy for the treatment of osteosarcoma.

Authors:  Paul A Meyers; John H Healey; Alexander J Chou; Leonard H Wexler; Pamela R Merola; Carol D Morris; Michael P Laquaglia; Michael G Kellick; Sara J Abramson; Richard Gorlick
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

7.  Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis.

Authors:  Liliana Montella; Carmela Merola; Geraldina Merola; Luigi Petillo; Giovannella Palmieri
Journal:  J Bone Miner Metab       Date:  2008-11-19       Impact factor: 2.626

8.  Morphoproteomics provides support for TGF-β pathway signaling in the osteoclastogenesis and immune dysregulation of osteolytic Langerhans cell histiocytosis.

Authors:  Sanda Alexandrescu; Nina Tatevian; Bogdan A Czerniak; Michael H Covinsky; Nadja K Burns; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2012-07-29

Review 9.  Langerhans cell histiocytosis.

Authors:  Kevin Bradford Hoover; Daniel I Rosenthal; Henry Mankin
Journal:  Skeletal Radiol       Date:  2006-10-07       Impact factor: 2.128

Review 10.  Langerhans cell histiocytosis.

Authors:  Joan Manel Gasent Blesa; Vicente Alberola Candel; Carlos Solano Vercet; Juan Laforga Canales; Christof Semler; Maria Rosa Pérez Antolí; Carlos Rodríguez-Galindo
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.340

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.